Company Overview of Wyeth Pharmaceuticals, Inc.
Wyeth Pharmaceuticals, Inc. develops, manufactures, and markets pharmaceutical products to treat cardiovascular and gastrointestinal diseases, infectious diseases, cancer, women's health concerns, and depression. It offers antidepressant Effexor, estrogen replacement therapy Premarin, and acid reflux disease drug Protonix; XYNTHA, a recombinant factor VIII product for the control and prevention of bleeding episodes and surgical prophylaxis; and Prevnar 13, a pneumococcal 13-valent conjugate vaccine. The company also offers vaccines and nutritional products, including infant formulas and adult supplements. It serves health care professionals and patients in the United States and Canada. The c...
500 Arcola Road
Collegeville, PA 19426
Founded in 2002
Key Executives for Wyeth Pharmaceuticals, Inc.
Chief Financial Officer and Executive Vice President
President of Europe, Middle East, Africa & Canada
Executive Vice President of Vaccines Research & Development
Compensation as of Fiscal Year 2014.
Wyeth Pharmaceuticals, Inc. Key Developments
Attorneys General Reaches Settlement Agreement with Wyeth Pharmaceuticals Inc
Aug 6 14
Texas Attorney General Greg Abbott and 41 other state attorneys general secured a $35 million agreement with Wyeth Pharmaceuticals Inc. The agreement resolves a multistate investigation against Wyeth for unlawfully promoting its immunosuppressive drug Rapamune. Under the settlement agreement, Pfizer must pay the State of Texas a total of $2.387 million. The agreement orders $1.591 million of the settlement funds to be disbursed to the General Revenue or the Supreme Court Judicial Fund, as appropriate, pursuant to Texas Government Code Sec. 402.007. The remaining funds will reimburse the State's legal fees.
Wyeth Pharmaceuticals, Inc. Settles Suit over Transplant Drug for $490 Million
Aug 9 13
Wyeth Pharmaceuticals, Inc. will pay $490 million to resolve allegations that it promoted one of its drugs for off-label uses. The Food and Drug Administration approved Rapamune in 1999 for use by kidney transplant patients. Rapamune is an immunosuppressive drug that prevents the body from rejecting a transplanted organ. Wyeth marketed the drug for patients who had transplants involving organs other than kidneys without prior approval. The settlement includes a criminal fine of $157.58 million and forfeiture of $76 million in assets. It also includes a $257.4 million civil settlement.
US Justice Department Fines Wyeth Pharmaceuticals $490.9 Million for Illegal Drug Marketing
Jul 30 13
Wyeth Pharmaceuticals has pleaded guilty to misbranding a drug that prevents the rejection of organ transplants and agreed to pay $490.9 million. The $490.9 million will resolve Wyeth's criminal and civil liability stemming from the unlawful marketing of the prescription drug Rapamune for uses not approved as safe and effective by the US Food and Drug Administration. The company, under a plea agreement that has been accepted by the US District Court in Oklahoma City, also has agreed to pay a criminal fine of $157.58 million and forfeit assets of $76 million.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries